Abstract
Background Cue reactivity is one of the most frequently used paradigms in functional magnetic resonance imaging (fMRI) studies of substance use disorders (SUDs). Although there have been many promising results elucidating the neurocognitive mechanisms of SUDs and SUD treatments, heterogeneities in participant characteristics, task design, craving assessment, scanning preparation and analysis decisions limit rigor and reproducibility in the field of fMRI of drug cue reactivity (FDCR), hampering clinical translation and synthesis by systematic reviews and meta-analyses. The aim of this consensus paper and Delphi study is to outline the important methodological aspects of FDCR studies and present a list of items and recommendations that should be taken into account when designing FDCR studies and reporting their results.
Methods Fifty-five FDCR scientists from around the world participated. First, an initial checklist of items deemed important in FDCR studies was developed by a group of members from the ENIGMA Addiction Consortium based on a systematic review. Then, using a modified Delphi consensus method, all experts were asked to comment on, revise or add items to the initial checklist. Subsequently, experts were asked to rate the importance of the items.
Results Thirty-seven items were proposed in the first round. After the commenting phase, seven new items suggested by experts were added and six were removed. The final 38 items that reached a defined consensus threshold in the rating phase were classified under seven categories and are considered important for conducting and reporting in any FDCR study.
Conclusion This paper proposes a list of items and additional recommendations that researchers in the field of FDCR are encouraged to note and report when designing an FDCR study and reporting its results. Along with the presentation of a quality control checklist with Yes/No ratable items, various challenges in moving towards greater homogeneity in FDCR research and widespread use of FDCR to investigate SUDs and develop clinically relevant biomarkers are discussed.
Competing Interest Statement
Raymond F. Anton is Chair of the American Society of Clinical Psychopharmacology's Alcohol Clinical Trials Initiative (ACTIVE Group), which has received support in the past 36 months by: Alkermes, Amygdala Neurosciences, Arbor Pharmaceuticals, Dicerna, Ethypharm, Indivior, Lundbeck, Mitsubishi, and Otsuka. He has been a recent consultant for Allergan, Alkermes, Dicerna, Insys, Laboratorio Pharmaceutico and Life Technologies, as well as receiving grant funding from Laboratorio Pharmaceutico. Amy C. Janes consults for Axial Biotherapeutics. Marc Potenza consulted for and advised the Addiction Policy Forum, Game Day Data, AXA, Idorsia and Opiant/Lakelight Therapeutics; received research support from the Mohegan Sun Casino and the National Center for Responsible Gaming (now the International Center for Responsible Gaming); consulted for legal and gambling entities on issues related to impulse-control and addictive disorders; given academic lectures in grand rounds, CME events, and other clinical/scientific venues; and generated books or chapters for publishers of mental health texts. Joseph P. Schacht has consulted for and received grant funding from Laboratorio Farmaceutico CT. Other authors declare no competing interests.
Funding Statement
Raymond F. Anton is supported by NIAAA P50 AA010761. Patrick Bach is supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Project-ID 402170461 TRR 265 (Heinz et al., Addict Biol. 2019). Anne Beck is supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Project-ID 402170461 TRR 265-project C02 (Heinz et al., Addict Biol. 2019). Kelly E. Courtney is supported by the California Tobacco-Related Disease Research Grant Program of the University of California grant number T30IP0962. Hamed Ekhtiari is supported by the Laureate Institute for Brain Research (LIBR), Warren K. Family Foundation, Oklahoma Center for Advancement of Science and Technologies (OCAST, #HR18-139) and Brain and Behavior Foundation (NARSAD Young Investigator Award #27305). Francesca M. Filbey is supported by the National Institute on Drug Abuse grants R01 DA030344 and R21DA044465. Rita Z. Goldstein is supported by NIDA grants R01DA041528, R01DA048301 and R01DA047851 and NCCIH grant R01AT010627. Erica Grodin is supported by the National Institute on Alcohol Abuse and Alcoholism grant F32AA027699. Andreas Heinz is supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Project-ID 402170461 TRR 265 (Heinz et al., Addict Biol. 2019). Amy C. Janes is supported by R01DA039135 and K02DA042987. Marc J. Kaufman is supported with R01 DA041866. Hamid R Noori is supported by the Bundesministerium fur Bildung und Forschung (e:Med program: FKZ: 01ZX1503 and 01ZX1909B), and the Deutsche Forschungsgemeinschaft (TRR 265A05). Stephane Potvin is holder of Eli Lilly Canada Chair on schizophrenia research. Joseph P. Schacht is supported by NIAAA grants R01 AA027765 and R01 AA026859. Dongju Seo is supported by R01AA026844 and K08AA023545. Vaughn R. Steele is partially funded by the National Institute on Drug Abuse (NIDA) grant K12 DA000167. Susan F. Tapert is supported by NIAAA grants U01 AA021692 and U24 AA021695, and NIDA grants U01 DA041089 and U24 DA041147. Sabine Vollstaedt-Klein is supported by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation): Project ID 402170461 (Heinz et al., Addict Biol. 2019), Project ID-421888313, Project ID 437718741 and Project-ID 324164820. Reagan Wetherill is supported by K23AA023894, R01DA040670, and R21HL144673. Stephen J. Wilson is supported by R01DA041438 and R21DA045853. Katie Witkiewitz is supported by the National Institute on Alcohol Abuse and Alcoholism grants R01AA023665 and R01AA022328. Kai Yuan is supported by the National Natural Science Foundation of China (Grant No. 81871426). Anna Zilverstand is supported by NIDA grants P30 DA048742 and R01DA047851. The views presented in this manuscript represent those of the authors and not necessarily those of the funding agencies.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The protocol of this study is being reviewed and approved by the independent ethics committee of the Iran University of Medical Sciences (IR.IUMS.REC.1399.530).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data of this project is partially available at https://osf.io/gwrh6/. Other details are available upon appropriate requests from the corresponding author.
